Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

MPE gives feedback on the proposed implementing act supporting the EU Health Technology Assessment regulation

The European Commission recently held an online public consultation on the first draft implementing act supporting the EU health technology assessment (HTA) regulation. The EU HTA regulation will be implemented from 2025 and aims to increase the collaboration on health technology assessment across EU member states. Implementing acts set out the legislative detail of different…

Read more

Sign up for the MPE webinar “AL amyloidosis treatment updates and patient experiences on new therapies”

Myeloma Patients Europe (MPE) will hold the webinar “AL amyloidosis treatment updates and patient experiences on new therapies” on Tuesday 16 April from 17:00 – 18:00 CEST. The webinar will be given by Dr. Moshe Gatt, Physician Researcher Haematologist at the Hebrew University of Jerusalem, Israel, along with two AL Amyloidosis patients from Israel, Naphtali Mastboim and Melvin Granatstein, who…

Read more

European Commission grants final approval for CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myeloma

The European Commission has granted the final approval for the extension of the marketing authorisation for idecabtagene vicleucel (ide-cel), a CAR-T treatment marketed by Bristol-Myers Squibb (BMS) as Abecma®. Ide-cel has previously been approved for the treatment of patients with relapsed and refractory myeloma, who have received at least three previous lines of therapy. The…

Read more

EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myeloma

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA – the EU medicines regulator) has today given a positive recommendation for the extension of the marketing authorisation for the CAR-T treatment ciltacabtagene autoleucel (Carvytki®), also known as cilta-cel, for use in patients who have received at least 1 prior…

Read more
May

June 2026

July
MO
TU
WE
TH
FR
SA
SU
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
4
5
Events for 1st June
No Events
Events for 2nd June
No Events
Events for 3rd June
No Events
Events for 4th June
No Events
Events for 5th June
No Events
Events for 6th June
No Events
Events for 7th June
No Events
Events for 8th June
No Events
Events for 9th June
No Events
Events for 10th June
No Events
Events for 11th June
No Events
Events for 12th June
No Events
Events for 13th June
No Events
Events for 14th June
No Events
Events for 15th June
No Events
Events for 16th June
No Events
Events for 17th June
No Events
Events for 18th June
No Events
Events for 19th June
No Events
Events for 20th June
No Events
Events for 21st June
No Events
Events for 22nd June
No Events
Events for 23rd June
No Events
Events for 24th June
No Events
Events for 25th June
No Events
Events for 26th June
No Events
Events for 27th June
No Events
Events for 28th June
No Events
Events for 29th June
No Events
Events for 30th June
No Events